Research and Markets has announced the addition of the "Trans Activator Of Transcription (TaT) - Pipeline Review, H2 2016" report to their offering.

Trans Activator Of Transcription (Tat) - Pipeline Review, H2 2016', provides in depth analysis on Trans Activator Of Transcription (Tat) targeted pipeline therapeutics.

The report provides comprehensive information on the Trans Activator Of Transcription (Tat), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in Trans Activator Of Transcription (Tat) targeted therapeutics development and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Trans Activator Of Transcription Overview
  3. Therapeutics Development
  4. Pipeline Products for Trans Activator Of Transcription - Overview
  5. Pipeline Products for Trans Activator Of Transcription - Comparative Analysis
  6. Trans Activator Of Transcription - Therapeutics under Development by Companies
  7. Trans Activator Of Transcription - Therapeutics under Investigation by Universities/Institutes
  8. Trans Activator Of Transcription Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Trans Activator Of Transcription - Products under Development by Companies
  13. Trans Activator Of Transcription - Products under Investigation by Universities/Institutes
  14. Trans Activator Of Transcription - Companies Involved in Therapeutics Development

- Akshaya Bio Inc

- Biosantech SA

- Cannabis Science Inc

For more information about this report visit http://www.researchandmarkets.com/research/xh67m2/trans_activator